Cargando…
The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
Invasive fungal diseases (IFD) remain a major cause of morbidity and mortality in hematological patients, especially those undergoing hematopoietic stem cell transplantation (HSCT). Despite relatively high incidence, diagnosis and treatment remain a challenge due to non-specific manifestation and li...
Autores principales: | Daraskevicius, Justinas, Petraitis, Vidmantas, Davainis, Linas, Zucenka, Andrius |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144376/ https://www.ncbi.nlm.nih.gov/pubmed/35628696 http://dx.doi.org/10.3390/jof8050440 |
Ejemplares similares
-
Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
por: Zucenka, Andrius, et al.
Publicado: (2021) -
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021) -
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
por: Grant, Leah M., et al.
Publicado: (2022) -
Outcomes and Risk Factors of Critically Ill Patients with Hematological Malignancy. Prospective Single-Centre Observational Study
por: Judickas, Šarūnas, et al.
Publicado: (2021) -
Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections
por: Angulo, David A., et al.
Publicado: (2022)